85 related articles for article (PubMed ID: 33221577)
1. Rise of levels of von Willebrand factor and factor VIII with age: Role of genetic and acquired risk factors.
Biguzzi E; Castelli F; Lijfering WM; Cannegieter SC; Eikenboom J; Rosendaal FR; van Hylckama Vlieg A
Thromb Res; 2021 Jan; 197():172-178. PubMed ID: 33221577
[TBL] [Abstract][Full Text] [Related]
2. Coagulation factor VIII regulates von Willebrand factor homeostasis invivo.
Cao W; Trask AR; Bignotti AI; George LA; Doshi BS; Sabatino DE; Yada N; Zheng L; Camire RM; Zheng XL
J Thromb Haemost; 2023 Dec; 21(12):3477-3489. PubMed ID: 37726033
[TBL] [Abstract][Full Text] [Related]
3. Targeting a higher plasma VWF level at time of delivery in pregnant individuals with von Willebrand disease: Outcomes at a single-institution cohort study.
Lim MY; Rodgers GM; Branch DW; Simonsen SE
Haemophilia; 2024 Mar; 30(2):470-477. PubMed ID: 38343098
[TBL] [Abstract][Full Text] [Related]
4. Gene-centric approach identifies new and known loci for FVIII activity and VWF antigen levels in European Americans and African Americans.
Tang W; Cushman M; Green D; Rich SS; Lange LA; Yang Q; Tracy RP; Tofler GH; Basu S; Wilson JG; Keating BJ; Weng LC; Taylor HA; Jacobs DR; Delaney JA; Palmer CD; Young T; Pankow JS; O'Donnell CJ; Smith NL; Reiner AP; Folsom AR
Am J Hematol; 2015 Jun; 90(6):534-40. PubMed ID: 25779970
[TBL] [Abstract][Full Text] [Related]
5. A genetic association study of circulating coagulation factor VIII and von Willebrand factor levels.
de Vries PS; Reventun P; Brown MR; Heath AS; Huffman JE; Le NQ; Bebo A; Brody JA; Temprano-Sagrera G; Raffield LM; Ozel AB; Thibord F; Jain D; Lewis JP; Rodriguez BAT; Pankratz N; Taylor KD; Polasek O; Chen MH; Yanek LR; Carrasquilla GD; Marioni RE; Kleber ME; Trégouët DA; Yao J; Li-Gao R; Joshi PK; Trompet S; Martinez-Perez A; Ghanbari M; Howard TE; Reiner AP; Arvanitis M; Ryan KA; Bartz TM; Rudan I; Faraday N; Linneberg A; Ekunwe L; Davies G; Delgado GE; Suchon P; Guo X; Rosendaal FR; Klaric L; Noordam R; van Rooij F; Curran JE; Wheeler MM; Osburn WO; O'Connell JR; Boerwinkle E; Beswick A; Psaty BM; Kolcic I; Souto JC; Becker LC; Hansen T; Doyle MF; Harris SE; Moissl AP; Deleuze JF; Rich SS; van Hylckama Vlieg A; Campbell H; Stott DJ; Soria JM; de Maat MPM; Almasy L; Brody LC; Auer PL; Mitchell BD; Ben-Shlomo Y; Fornage M; Hayward C; Mathias RA; Kilpeläinen TO; Lange LA; Cox SR; März W; Morange PE; Rotter JI; Mook-Kanamori DO; Wilson JF; van der Harst P; Jukema JW; Ikram MA; Blangero J; Kooperberg C; Desch KC; Johnson AD; Sabater-Lleal M; Lowenstein CJ; Smith NL; Morrison AC
Blood; 2024 May; 143(18):1845-1855. PubMed ID: 38320121
[TBL] [Abstract][Full Text] [Related]
6. The influence of von Willebrand factor on factor VIII activity measurements.
Butenas S; Parhami-Seren B; Mann KG
J Thromb Haemost; 2009 Jan; 7(1):132-7. PubMed ID: 18983499
[TBL] [Abstract][Full Text] [Related]
7. Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia.
Sacco M; Ranalli P; Lancellotti S; Petrucci G; Dragani A; Rocca B; De Cristofaro R
Res Pract Thromb Haemost; 2020 Mar; 4(3):413-421. PubMed ID: 32211575
[TBL] [Abstract][Full Text] [Related]
8. Dynamic and functional linkage between von Willebrand factor and ADAMTS-13 with aging: an Atherosclerosis Risk in Community study.
Liu W; Patel K; Wang Y; Nodzenski M; Nguyen A; Teramura G; Higgins HA; Hoogeveen RC; Couper D; Fu X; Konkle BA; Loop MS; Dong JF
J Thromb Haemost; 2023 Dec; 21(12):3371-3382. PubMed ID: 37574196
[TBL] [Abstract][Full Text] [Related]
9. The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease.
Scheiner B; Northup PG; Gruber AB; Semmler G; Leitner G; Quehenberger P; Thaler J; Ay C; Trauner M; Reiberger T; Lisman T; Mandorfer M
Liver Int; 2020 Jun; 40(6):1415-1426. PubMed ID: 32052552
[TBL] [Abstract][Full Text] [Related]
10. Prolonged Elevations of Factor VIII and von Willebrand Factor Antigen After Multisystem Inflammatory Syndrome in Children.
Boucher AA; Knutson S; Young L; Evans MD; Braunlin E; Zantek ND; Sharon B; Binstadt BA; Ryan M; Greene R; Mahmud S; Marmet J; Fischer G; Steiner ME
J Pediatr Hematol Oncol; 2023 May; 45(4):e427-e432. PubMed ID: 36730963
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Laboratory Presentation and Underlying Mechanism in Patients with Low VWF.
Seidizadeh O; Ciavarella A; Baronciani L; Boggio F; Ballardini F; Cozzi G; Colpani P; Pagliari MT; Novembrino C; Siboni SM; Peyvandi F
Thromb Haemost; 2024 Apr; 124(4):340-350. PubMed ID: 37799090
[TBL] [Abstract][Full Text] [Related]
12. A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels.
Viel KR; Machiah DK; Warren DM; Khachidze M; Buil A; Fernstrom K; Souto JC; Peralta JM; Smith T; Blangero J; Porter S; Warren ST; Fontcuberta J; Soria JM; Flanders WD; Almasy L; Howard TE
Blood; 2007 May; 109(9):3713-24. PubMed ID: 17209060
[TBL] [Abstract][Full Text] [Related]
13. Von Willebrand Factor Antigen Levels Predict Poor Outcomes in Patients With Stroke and Cancer: Findings From the Multicenter, Prospective, Observational SCAN Study.
Kawano T; Gon Y; Sakaguchi M; Yamagami H; Abe S; Hashimoto H; Ohara N; Takahashi D; Abe Y; Takahashi T; Okazaki S; Todo K; Mochizuki H; Sasaki T;
J Am Heart Assoc; 2024 Feb; 13(3):e032284. PubMed ID: 38240254
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers of thromboinflammation correlate to COVID-19 infection and admission status in emergency department patients.
Goswami J; MacArthur TA; Sridharan M; Tange J; Kirmse AJ; Lundell KA; Chen D; Auton MT; Chon TY; Hurt RT; Salonen BR; Ganesh R; Erben YM; Marquez CP; Dong JF; Kozar RA; Heller SF; Loomis EA; Johnstone AL; Bailey KR; Spears GM; Park MS
Thromb Update; 2021 Dec; 5():100090. PubMed ID: 38620680
[TBL] [Abstract][Full Text] [Related]
15. Factor VIII as a Novel Biomarker for Diagnosis, Prognosis, and Therapy Prediction in Human Cancer and Other Disorders.
Khalilian S; Mohajer Z; Ghafouri-Fard S
Avicenna J Med Biotechnol; 2024; 16(2):68-80. PubMed ID: 38618505
[TBL] [Abstract][Full Text] [Related]
16. O blood type is not associated with worse coagulopathy or outcome in exsanguinating trauma.
Gwin JC; Rangnekar N; Murray GP; Byerly S; Fleming AM; Easterday TS; Kerwin AJ; Howley IW
Am J Surg; 2024 Mar; ():. PubMed ID: 38553336
[TBL] [Abstract][Full Text] [Related]
17. ABO Histo-Blood Group and the von Willebrand Factor Axis in Severe COVID-19.
Reilly JP; Shashaty MGS; Miano TA; Giannini HM; Jones TK; Ittner CAG; Christie JD; Meyer NJ
CHEST Crit Care; 2023 Dec; 1(3):. PubMed ID: 38130415
[No Abstract] [Full Text] [Related]
18. The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development.
Reipert BM; Gangadharan B; Hofbauer CJ; Berg V; Schweiger H; Bowen J; Blatny J; Fijnvandraat K; Mullins ES; Klintman J; Male C; McGuinn C; Meeks SL; Radulescu VC; Ragni MV; Recht M; Shapiro AD; Staber JM; Yaish HM; Santagostino E; Brown DL
Blood Adv; 2020 Nov; 4(22):5785-5796. PubMed ID: 33232473
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and efficacy of emicizumab for up to 5.8 years and patients' perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A.
Shima M; Nagao A; Taki M; Matsushita T; Oshida K; Amano K; Nagami S; Okada N; Maisawa S; Nogami K
Haemophilia; 2021 Jan; 27(1):81-89. PubMed ID: 33236410
[TBL] [Abstract][Full Text] [Related]
20. Comparison of bypassing agents in patients on emicizumab using global hemostasis assays.
Kizilocak H; Marquez-Casas E; Phei Wee C; Malvar J; Carmona R; Young G
Haemophilia; 2021 Jan; 27(1):164-172. PubMed ID: 33245833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
